Cowen Investment Management’s Adicet Bio ACET Stock Holding History

Cowen Investment Management’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-866	Closed	-$100K	–	49
2020 Q1	$100K	Buy	+866	New	+$129K	0.06%	33

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Cowen Investment Management's ACET Position: Q2 2020 in Review

Cowen Investment Management sold out of Adicet Bio (ACET) in Q2 2020, closing a stake of 866 shares — an estimated $100K sold.

Cowen Investment Management first reported a position in ACET in Q1 2020 and held it in 1 quarter. The position peaked at $100K in Q1 2020. 53 funds tracked by Wall St. Rank hold ACET as of Q2 2020.

Cowen Investment Management reported no remaining Adicet Bio position as of Q2 2020 after selling out during the quarter.
Cowen Investment Management sold 866 Adicet Bio shares in Q2 2020, an estimated $100K.
Cowen Investment Management first reported a position in Adicet Bio in Q1 2020 and held it in 1 quarter.
Cowen Investment Management's Adicet Bio position peaked at $100K in Q1 2020.
53 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2020.

Based on Cowen Investment Management's 13F filing for Q2 2020, filed 12 Aug 2020.